The selective proteasome inhibitor carfilzomib has previously shown efficacy in terms of progression-free survival (PFS) for relapsed multiple myeloma (MM). From the 23rd Congress of the European Hematology Association (EHA) 2018, held in Stockholm, Sweden, Katja Weisel, MD, from University Hospital Tubingen, Tubingen, Germany, presents updates on the ASPIRE trial (NCT01080391), a Phase III study that demonstrated that carfilzomib in combination with lenalidomide and dexamethasone (KRd) improved not just PFS, but overall survival as well. Prof. Weisel also provides updates on the POLLUX (NCT02076009) and CASTOR (NCT02136134) twin Phase III trials, which investigated daratumumab combinations across different risk groups, showing high response rates and strong hazard ratios.
Carfilzomib for relapsed multiple myeloma: clinical trial updates
